Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polivy plus R-GEMOX vs R-GEMOX in relapsed/refractory DLBCL
2024-512537-33-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Roche. Primary endpoints: Incidence, nature and severity of physical findings and adverse events (Stage 1) and Overall survival (Stage 2). Started Jul 2024; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-512537-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512537-33-00.